Paul

Dr Brooks joined CN Bio Innovations in 2022. He has over 25 years of experience in building businesses and leading high-performance research, product, marketing, and sales teams to develop and commercialize new biotechnology technologies globally for drug discovery, bioproduction and diagnostics.

Dr Brooks has held senior leadership positions in the USA and the UK, including Head of Business Operations and Managing Director of Horizon Discovery Ltd; Chief Commercial Officer and Executive Board member of Oxford Genetics Ltd; Head of Discovery Research Services at MilliporeSigma (Merck KGaA); and Global Marketing Manager at Sigma-Aldrich Corp. Dr Brooks has a BSc in Biochemistry from the University of Wales, a PhD in Molecular Biology from the University of Manchester Institute of Science and Technology (UMIST), and an MBA from the University of Nottingham Business School.

Tomasz

Dr Kostrzewski has more than 15 years of experience in molecular and cellular biology research. He joined CN Bio in 2015 and was promoted to Director of Biology in 2018 with responsibility for biological model development and collaborative research projects with academia, pharma, and regulators. In 2021 he was promoted to VP of Science and Technology and then to Chief Scientific Officer in 2023, with responsibility for all technical activities, including developing new products, technologies, and assays, as well as contract research services. Dr Kostrzewski has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. He has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications.

Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation, as well as at GlaxoSmithKline working in biopharmaceutical drug discovery and development. Dr Kostrzewski holds three degrees from the University of Sheffield and Imperial College London in Cell and Molecular Biology.

Audrey

Dr Audrey Dubourg is CN Bio’s Product Manager for the PhysioMimix® OOC range of microphysiological systems. Prior to joining CN Bio, she worked as a postdoctoral scholar at the University of California – Los Angeles (UCLA), in the US, in the Microbiology, Immunology and Molecular Genetics department. She completed an MSc in microbiology at the University of Montpellier II, followed by a PhD in microbiology/parasitology at the University of East Anglia. Audrey has extensive experience in the disciplines of molecular biology and 3D mammalian cell culture. Since joining CN Bio, she has been actively involved in promoting the benefits of incorporating organ-on-a-chip technology into drug discovery and development workflows.

Joe

Joe Parisi is a Commercial Leader with 14 years’ experience in the life science sector. Joe joined CN Bio as the Americas Director of Sales in December 2023. He comes to CN Bio with valuable startup experience most recently at IsoPlexis and Purigen Biosystems, where he was responsible for building commercial opportunities across the US West. He was previously Sales Director at PhenomeX (now Bruker Cellular Analysis), where he managed the proteomics team in the US West focusing on capital equipment sales for single-cell functional analysis. Joe graduated from the University of Illinois Champaign-Urbana with a BSc in Molecular and Cellular Biology.

Emily

Dr Emily Richardson is a Lead Scientist in the R&D team at CN Bio. She joined the team in 2020 as a Senior Scientist and lead the development of the PhysioMimix lung and lung-liver MPS models. Emily is highly experienced in the application of complex cell biology to drug discovery, having previously worked in cellular therapeutics in an industry setting and as a trained biochemist with specialty in molecular biology. She completed her PhD at the University of Leicester, using 3D cell culture to determine molecular mechanisms driving highly metastatic lung cancers. She now leads R&D projects within the CN Bio team revolving around toxicology in the liver and the lung MPS, as well as driving collaborative projects with various academic, industry and regulatory partners.

Ovi

Dr Ovidiu Novac is a Senior Scientist at CN Bio and a knowledgeable organ-on-a-chip (OOC) expert. Ovi performed as lead biological scientist in the NASH-in-a-Box project, is a knowledgeable organ-on-a-chip (OOC) expert, and has experience in assessing drug induced liver injury in vitro. Ovi has a background in the developmental stage of pharmaceutical and dermatological formulations and their performance assessment on human skin tissue ex vivo (topical and transdermal), and for strategic planning for further evaluation. During time spent in the pharma industry he contributed to delivering high quality results used for marketing purposes and in regulatory submissions. Ovi holds a BSc in biomaterials and prosthetic technologies and a PhD in chemistry and has been involved in research on controlled drug delivery systems since 2006.

Scott

Dr Scott Chilton is the Eastern US Sales Manager for CN Bio, based in Massachusetts, USA.  Scott supports researchers who want to develop safe and effective therapeutics faster and more cost-effectively by adopting solutions that provide physiologically relevant and clinically translatable data.  Scott holds a PhD from Harvard University and a BS from Massachusetts Institute of Technology.

Anthony

Dr. Anthony Berger is CN Bio’s US-based Field Application Scientist, providing support for the PhysioMimix® Organ-on-Chip benchtop platform. Anthony has an extensive research background in 3D cell culture, biomaterials, and microfluidics, focusing on how the microenvironment influences cellular decision-making. He is a proponent of complex 3D in vitro models and desires to decrease the barrier to entry of these technologies. Anthony received his BS from Indiana University (US), PhD from the University of Wisconsin (US), and completed a postdoctoral fellowship at Temple University (US).

Dave

Dave recently joined CN Bio in February 2024 as Sales Manager for the Western U.S. Dave brings 20+ years of award-winning lab platform sales experience across several different diagnostics markets. In the past 10 years, he gained valuable experience expanding business into molecular reference labs and biotech’s in the West area. Most recently, Dave was the Regional Business Manager at Bionano Genomics selling Optical Genome Mapping on Saphyr System to Biotech’s who specialize in Cell and Gene Tx space. Dave looks forward to being a part of moving CN Bio Organ-on-a-Chip technology from start up to scale in the next few years.